Back to User profile » Dr Johnson

Paper published by Dr Johnson:


Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

Nelson V, Ziehr J, Agulnik M, Johnson M

OncoTargets and Therapy 2013, 6:135-143

Published Date: 5 March 2013